Medtronic plc News
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
see moreMedtronic plc Market News
5d
Medtronic Shift: MiniMed IPO, Robotics & Liability
- Medtronic's recent MiniMed IPO, FDA clearances for new robotic spine and surgical platforms, and a Supreme Court ruling narrowing liability for FDA-approved devices together reshape MDT's risk profile and strategic focus. These concrete events can materially influence investor valuation and capital allocation.
12d
Medtronic Q3 Gains, Diabetes Spin-Off Uncertainty.
Medtronic reported a solid Q3 with revenue growth, key device approvals and strong cardiac ablation performance, but investor enthusiasm was tempered by a planned Diabetes spin-off and tariff-driven margin pressure.
19d
Medtronic's MiniMed IPO Sparks Q3 Growth Surge
Medtronic’s MiniMed IPO plans and a strong Q3 performance — led by Pulsed Field Ablation and robotics — have reinvigorated investor interest in MDT. Near-term upside is balanced by tariff headwinds and execution risk as the company navigates a multi-product launch cycle.
26d
Medtronic Hit by $382M Verdict; Catalysts Ahead Q1
Medtronic (MDT) faced a $382M antitrust verdict this week that pressures near-term results, while strategic moves—an acquisition of CathWorks, diabetes device approvals and Medicare coverage—reinforce long-term growth pathways. Mixed Q3 results, tariff exposure and cautious guidance kept investor sentiment muted despite an analyst upgrade.
17 Feb at 14:15
Medtronic Q3 Beat, Guidance Leaves Investors Cold.
Medtronic reported a modest Q3 beat in revenue and adjusted EPS but kept full-year guidance unchanged. Tariff-related costs and cautious outlook pressured MDT shares, with elevated trading volume suggesting institutional repositioning.
10 Feb at 14:15
Medtronic Catalysts: CathWorks Buy, Diabetes Wins!
Medtronic (MDT) saw near‑term share pressure even as the company secured regulatory wins for its MiniMed 780G insulin platform and moved toward acquiring CathWorks, an AI cardiac-imaging firm. Recent analyst upgrades, Medicare coverage, and product clearances create tangible growth catalysts for the diabetes and cardiology franchises.